Australia markets closed
  • ALL ORDS

    6,720.40
    -26.10 (-0.39%)
     
  • ASX 200

    6,539.90
    -28.20 (-0.43%)
     
  • AUD/USD

    0.6808
    -0.0097 (-1.40%)
     
  • OIL

    107.51
    +1.75 (+1.65%)
     
  • GOLD

    1,792.50
    -14.80 (-0.82%)
     
  • BTC-AUD

    28,594.05
    +324.13 (+1.15%)
     
  • CMC Crypto 200

    418.95
    -12.52 (-2.90%)
     
  • AUD/EUR

    0.6501
    -0.0080 (-1.21%)
     
  • AUD/NZD

    1.1027
    -0.0023 (-0.21%)
     
  • NZX 50

    10,753.16
    -115.54 (-1.06%)
     
  • NASDAQ

    11,503.72
    -154.55 (-1.33%)
     
  • FTSE

    7,191.56
    +22.28 (+0.31%)
     
  • Dow Jones

    30,775.43
    -253.88 (-0.82%)
     
  • DAX

    12,820.29
    +36.52 (+0.29%)
     
  • Hang Seng

    21,859.79
    -137.10 (-0.62%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     

Loss-making Alignment Healthcare (NASDAQ:ALHC) has seen earnings and shareholder returns follow the same downward trajectory over past -53%

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Alignment Healthcare, Inc. (NASDAQ:ALHC) shareholders should be happy to see the share price up 15% in the last month. But that's not enough to compensate for the decline over the last twelve months. During that time the share price has sank like a stone, descending 53%. The share price recovery is not so impressive when you consider the fall. You could argue that the sell-off was too severe.

While the stock has risen 9.1% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

Check out our latest analysis for Alignment Healthcare

Alignment Healthcare isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last twelve months, Alignment Healthcare increased its revenue by 24%. We think that is pretty nice growth. Meanwhile, the share price tanked 53%, suggesting the market had much higher expectations. It is of course possible that the business will still deliver strong growth, it will just take longer than expected to do it. For us it's important to consider when you think a company will become profitable, if you're basing your valuation on revenue.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

We doubt Alignment Healthcare shareholders are happy with the loss of 53% over twelve months. That falls short of the market, which lost 10%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. Putting aside the last twelve months, it's good to see the share price has rebounded by 13%, in the last ninety days. Let's just hope this isn't the widely-feared 'dead cat bounce' (which would indicate further declines to come). While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Alignment Healthcare is showing 3 warning signs in our investment analysis , you should know about...

We will like Alignment Healthcare better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting